A novel-generation 3D bioreactor for rapid cell colonization in a 3D manner enabling an in vitro real reconstruction of tissue complexity, in an in vivo-like microenvironment.

Cat. No.




Ask a Quotation



3D bioreactor for 3D cell culture

6 pieces

General description

The 3D-matrix inner core is a fiber-based 3D scaffold, optimized for cell retainment, engrafment and colonization through the entire matrix thickness of 400 µm. The matrix empty volume of 90% is optimized for cell colonization.
The dimension of the device is compatible with current laboratory equipment, by using the tray provided which has been specifically developed for microscopies ad microplate readers. Optically transparent membranes allow real time growth monitoring by fluorescence microscopy and bioluminescence. The device is suitable for histology, immunofluorescence analysis, proteins and nucleic acids extraction, conditioned media collection, partial cell recovery.

Explore the VITVO experience…

Discover the VITVO advantages...

Handling VITVO…

Do you have any unmet need in your research?

Write us ​ to find out how VITVO can be useful for you!


Go on to discover more on VITVO features and applications!

VITVO Technical Specifications


Device Frame: TPE
3D Matrix: hydrophilically coated PBT
Oxygenation Membranes: PMP


Matrix volume: 4 cm2 (area) x 400 µm (thickness)
Empty volume: 90% of matrix volume


The automated fabrication is performed in the clean room, by the innovative technology without any additives and gluing agents

Biological safety

Inert, biocompatible and xeno-free
DNAse/RNAse free


Electron-beam processing

Storage and warehousing

Two years shelf life

RUO (research use only)

A Concrete Solution for the 3Rs

VITVO thanks to its peculiarities can host human and animal cells to at least reduce and replace small animal studies with both ethical and economic impacts in drug development.

VITVO positioning between the in vitro high throughput screening and the in vivo models will reduce costs of drug screening improving the reliability of pre-clinical testing for safety (i.e. normal hepatocytes) and efficacy (i.e. cancer cell lines or primary tumor cells).